Primary liver cancer cases are increasing rapidly, demanding enhanced screening and surgical readiness. Incidence and deaths have surged 59.4% and 55.8% from 2000 to 2023, respectively. Hepatitis B and C remain key causes, but rates have rebounded since 2020 despite prior declines. Surgeons must prioritize patient selection and intervention strategies, especially for patients with metabolic […]
Category: General Surgery
Assessing Secondary Cytoreductive Surgery for Colorectal Cancer
Secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival for select patients with recurrent colorectal cancer peritoneal metastases. Patients undergoing secondary surgery had an overall survival of 51.0 months compared to 24.0 months for those with initial treatment alone. No difference in postoperative complications was observed between initial and secondary procedures. Consider secondary surgery for […]
Neoadjuvant Strategies Yield Similar Results in Pancreatic Cancer
A meta-analysis finds that neoadjuvant chemoradiotherapy and chemotherapy have comparable outcomes for pancreatic ductal adenocarcinoma. Surgical resection rates were nearly identical: 68.9% for chemoradiotherapy versus 71.5% for chemotherapy. R0 resection rates were also similar: 70.7% for chemoradiotherapy and 64.2% for chemotherapy. Both treatment modalities produced similar one-year survival rates (71.3% versus 72.4%) and overall survival […]
Urine DNA Enhances Diagnosis of IPMN
A new study shows urine cell-free DNA can aid in diagnosing intraductal papillary mucinous neoplasms (IPMN), which may improve patient management. Urine cfDNA detected GNAS mutations in 32% and KRAS mutations in 58% of IPMN cases, compared to just 10% and 19% in plasma, respectively. Main pancreatic duct diameter ≥10 mm and urine mutations significantly […]
Resecting Colorectal Liver Metastases in Progressive Disease Improves Survival
Surgery for colorectal liver metastases after chemotherapy failure can offer survival benefits. Patients with progressive disease underwent hepatectomy showed a 5-year overall survival rate of 42.7%. This is lower than those with controlled disease (62.0% in complete/partial response and 55.5% in stable disease, p<0.001). However, resected progressive disease patients had better survival (46.5%) than non-resected […]
Lymph Node Harvest of 25+ Improves Survival in Esophageal Cancer
A multicenter study shows that removing at least 25 lymph nodes during surgery for esophageal adenocarcinoma post-chemotherapy leads to better outcomes. An optimal yield of 25 nodes resulted in a 29% reduction in mortality (HR: 0.714, p=0.0017) for chemotherapy patients. Those with ≥25 lymph nodes had approximately 44% lower mortality compared to chemoradiotherapy cases (HR=0.563, […]
Robotic Resection Works for Large Central Hepatic Tumors
Robotic liver surgery proves effective for complex resections of benign liver tumors like focal nodular hyperplasia. A 24-year-old woman underwent robotic partial hepatectomy for a growing 7 cm FNH with critical hilar involvement. The procedure lasted 3 hours with minimal blood loss (100 cc) and no complications. She was discharged on postoperative day 3, and […]
Robotic Gastrectomy Cuts Complications in Advanced Gastric Cancer
Robotic gastrectomy significantly lowers severe complications and boosts treatment outcomes in patients with advanced gastric cancer. Severe complications dropped to 2.6% with robotic surgery compared to 9.7% with laparoscopic (p=0.016). Chemotherapy completion improved to 63.6% in robotic cases versus 40.5% in laparoscopic (p=0.026). Higher estimated 5-year overall survival at 71.7% vs. 52.0% (p=0.046) for robotic […]
New G-CMAP Score Predicts Complications After Gastrectomy
A novel 8-point G-CMAP score can help surgeons predict postoperative complications after gastrectomy for gastric cancer, enhancing patient selection. Postoperative complications occurred in 18% of patients. Key predictors include C-reactive protein, monocyte count, serum albumin, and prothrombin time. This tool shows modest predictive ability (AUC 0.68) and can guide clinical decision-making for better surgical outcomes. […]
Navigating Evidence for Post-Pancreatoduodenectomy Fistulas
Surgeons need to balance level 1 evidence and experiential insight in mitigating pancreatic fistulas after pancreatoduodenectomy. Analysis of 37 randomized controlled trials reveals low patient inclusion rates (39.6%) and significant discord in findings for 6 of 7 mitigation techniques. Meta-analyses provided more consistent conclusions than individual trials, yet rates of clinically relevant fistulas differed notably […]